Efficacy and safety of intravenous Levetiracetam as first-line treatment for neonatal clinical seizures: A single-center study (2021−2023)

Intravenous levetiracetam demonstrated efficacy in controlling neonatal seizures, with no reported drug-related adverse effects. More than 70 % of neonates required only a single dose, and nearly 85 % remained seizure-free within 48 h. While these findings suggest favorable outcomes with levetiracetam, larger, prospective studies are necessary to further substantiate its efficacy and safety profile in this population.